Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Key Takeaway: Veradermics is set to hold a conference call to discuss the topline results from their Phase 2/3 study of VDPHL01, a treatment for males experiencing mild-to-moderate pattern hair loss. This call aims to provide insights into the study's findings and implications for future developments.